Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation.
Even though the overall outcome after allogeneic transplant has improved significantly in the last decades, late infectious diseases are still the most important causes of late morbidity and mortality. Here, impaired immune reconstitution and therapy of chronic graft-versus-host disease (GVHD) represent the major risk factors. In this review, we give a comprehensive overview of late infectious complications and summarize possible diagnostic and therapeutic interventions to prevent these complications.
Department of Internal Medicine II, Division of Hematology, University Hospital of Würzburg, Würzburg, Germany.
Shigeo
S
Fuji
Markus
M
Kapp
Hermann
H
Einsele
D002908:Chronic Disease; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D006086:Graft vs Host Disease / Q000150:complications / Q000191:economics / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006760:Hospitalization / Q000191:economics* / Q000706:statistics & numerical data*; D006801:Humans; D017053:Infection Control; D007239:Infections / Q000150:complications* / Q000175:diagnosis / Q000628:therapy; D017741:Survivors; D013997:Time Factors; D014184:Transplantation, Homologous